We found that the GEM is a local drug delivery (LDD) device capable of delivering gemcitabine to tumors and inhibiting tumor cell growth, angiogenesis, and metastasis by suppressing EGFR signaling pathways. The gene discussed is EGFR; the disease is neoplasm.